Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMML9AY)

• Drug Name: Indolin-2-one deriv. 4b Drug Info
• Synonyms: indolin-2-one deriv. 4b

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5329155
  CAS Number: CAS 288144-20-7
  TTD Drug ID: DMML9AY

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[3]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[5]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[6]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[7]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[9]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[10]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[11]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[2]

References

• [1] Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and P... J Med Chem. 1999 Dec 16;42(25):5120-30.
• [2] Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem. 2000 Jul 13;43(14):2655-63.
• [3] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [4] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [7] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [8] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [9] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [10] Clinical pipeline report, company report or official report of Exelixis (2011).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [12] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.